ÂÜÀòÂÒÂ×

Duyen Mai has worked in the pharmaceutical industry since 2006, beginning with ICOS Corporation as an Associate in Global Product Safety. Duyen then worked at Dendreon Corporation as an Associate Director of Drug Safety from 2007 to 2014, followed by Gilead Sciences as Senior Manager of REMS, Drug Safety & Public Health from 2014 to 2016. Duyen then worked at Juno Therapeutics, Inc. as Director of Pharmacovigilance from 2016 to 2019 before moving to Celgene as Director of US REMS Strategy & Policy from 2019 to 2020. Most recently, they have been working at Bristol Myers Squibb as Global Risk Management Lead of Cell Therapy since 2020 and is currently the Senior Director of Pharmacovigilance at Faraday Pharmaceuticals, Inc.

Duyen Mai obtained a Masters degree from the UCLA Fielding School of Public Health in Public Health, a BS degree from the University of Washington in Cell & Molecular Biology, and a BA degree from the University of Washington in American Ethnic Studies.